Administration of alpha4beta7 hetero-dimer-specific antibody
US9914779B2 · kind B2 · utility
2Cited by
0References
23Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 21, 2012 |
| Grant date | Mar 13, 2018 |
| Priority date | — |
| Expiry date | Dec 17, 2033 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/52
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
There is provided a method of treating a subject afflicted with a condition that is associated with inappropriate trafficking of cells expressing alpha4beta7 to the gastrointestinal tract, comprising administering to the subject an alpha4beta7 heterodimer specific antibody in an amount and at an interval sufficient to ameliorate the condition.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.